The Food and Drug Administration Center for Biological Evaluation and Research (CBER) is looking for small business sources that manufacture and sell mycobacteria culture systems to assess the anti-tuberculosis activity of the novel TB vaccines.
The center issued a sources sought notice this week to gather information on systems capable of performing fully automated susceptibility testing and result interpretation. Such systems must use oxygen consumption via fluorescent technology to monitor mycobacteria growth and hold at least 320 tubes at a time.
Responses to the sources sought announcement will assist the CBER in determining whether or not an actual future requirement similar to this one should be set aside for small business or made available to full and open competition.
Full details are available under Solicitation Number: FDA_12-223-SS-1104537. The solicitation response deadline is June 27, 2012.